Clinical trial
Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)
NCT00364286 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00364286 |
|---|---|
| Title | Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825) |
| Official title | Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825) |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphoma |
| Intervention type | Drug |
| Interventions | Dasatinib (BMS-354825) |
| Enrollment | 17 |
| Start date | Aug 1, 2006 |
| Primary completion | Nov 1, 2012 |
| Completion | Nov 1, 2012 |
| First posted | Aug 15, 2006 |
| Last update posted | Jan 20, 2026 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: